Latest Pharma Insights
Hanmi Secures North America Beachhead Via Aptose Acquisition
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Prebiotic Ingredient Firm Comet Forecasts Trail Of GLP-1 Popularity Driving Gut Health Concern
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Hanmi Secures North America Beachhead Via Aptose Acquisition
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Prebiotic Ingredient Firm Comet Forecasts Trail Of GLP-1 Popularity Driving Gut Health Concern
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Samsung Bioepis Pushes On With Pembrolizumab Phase III, Even As Others Terminate Trials
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Despite moves made by other developers to limit biosimilar trials – as regulators around the world move towards more streamlined models – Samsung Bioepis says it is sticking with a Phase III trial program for its SB27 proposed Keytruda (pembrolizumab) rival, having just completed recruitment.
Generics Bulletin - November 20, 2025
Isturisa’s FDA Label Expansion Sets Up Blockbuster Potential For Recordati
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
The Italian specialty pharma says an underdiagnosed patient population will drive multi-year growth for its steroidogenesis inhibitor.
Generics Bulletin - November 20, 2025
Nanomi Steps Into The Spotlight As Lupin Launches US Long-Acting Risperidone
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
Lupin’s US launch of its long-acting risperidone marks the first commercial use of Nanomi’s PrecisionSphere platform, validating a decade-long bet on complex injectables.
Generics Bulletin - November 20, 2025
ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
Deals In Depth: October 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
Podcast: Data-Driven Insights Reveal The Growth Engines Powering 2026 Life Sciences
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025